MYR Pharmaceuticals receives conditional marketing authorisation by European Commission for HEPCLUDEX
HEPCLUDEX has been approved as the first treatment option for adult patients with chronic hepatitis delta virus infection and compensated liver disease in Europe. The drug was originally
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.